Sage Therapeutics specializes in developing and selling drugs for central nervous system disorders such as postpartum depression (PPD) in adults, with its lead product candidate being 'ZULRESSO'. They also have other products in the pipeline such as 'zuranolone', for the treatment of major depressive disorders, treatment-resistant disorders, generalized anxiety disorders, and bipolar depression. Currently, Sage Therapeutics is collaborating with Shionogi & Co, Ltd. and Biogen MA Inc. for the development and commercialization of their products.